Results 231 to 240 of about 65,496 (283)

Assessment of thyroid cancer risk associated with glucagon‐like peptide 1 receptor agonist use

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1499-1507, February 2026.
Abstract Aims Published literature has raised concerns regarding a causal association between glucagon‐like peptide 1 receptor agonist (GLP‐1RA) use and thyroid cancer risk in adults. In this analysis, we evaluated the association between thyroid cancer risk and GLP‐1RA use.
Tina Vilsbøll, Michael Stellfeld, Vanita R. Aroda, Sune Dandanell, Jens‐Peter David, Ceyda T. P. Kristiansen, Søren Rasmussen, Fiona L. Roberts, Laszlo Hegedüs   +8 more
wiley   +1 more source

Dipeptidyl peptidase-4 deficiency prevents chronic stress-induced cardiac remodeling and dysfunction in mice. [PDF]

FASEB J
Jiang Z, Zhao L, Xin M, Wan Y, Xu S, Yue X, Jin X, Cui R, Li Y, Kim W, Wu H, Cheng XW.   +11 more
europepmc   +1 more source

New‐onset prediabetes/diabetes worsens overall survival in patients with cancer: A real‐world retrospective cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1247-1257, February 2026.
Abstract Aims Cancer diagnosis may increase the risk of developing prediabetes/diabetes and subsequently worsen survival in cancer patients. However, it is unclear whether this association is influenced by the timing of hyperglycemia onset or the use of antihyperglycemic medications.
Maci Winn, Svenja Pauleck, Stephanie Richardson, Richard Viskochil, Prasoona Karra, Howard Colman, Jennifer A. Doherty, Yizhe Xu, Siwen Hu‐Lieskovan, Michelle Litchman, Mary C. Playdon, Sheetal Hardikar   +11 more
wiley   +1 more source

Dipeptidyl peptidase 4 as an injury-responsive protein in the mouse sciatic nerve. [PDF]

Mol Cells
Oh Y, Cho Y.
europepmc   +1 more source

Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT‐J trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1278-1287, February 2026.
Abstract Aims This analysis aimed to assess the influence of selected baseline factors on tirzepatide treatment response in Japanese patients with obesity disease. Materials and Methods This was a prespecified subgroup analysis of the SURMOUNT‐J trial.
Koutaro Yokote, Yasushi Fukushima, Tomotaka Shingaki, Tomonori Oura, Wataru Ogawa   +4 more
wiley   +1 more source

Screening and Validation: AI-Aided Discovery of Dipeptidyl Peptidase-4 Inhibitory Peptides from Hydrolyzed Rice Proteins. [PDF]

Foods
Cheng C, Cui H, Yu X, Li W.
europepmc   +1 more source

Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1420-1430, February 2026.
Abstract Aims To assess whether periconceptional exposure to glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) is associated with adverse outcomes in women with pregestational type 2 diabetes. Materials and Methods We linked Taiwan's Birth Certificate Application and National Health Insurance claims (2013–2022) to assemble a nationwide cohort of ...
Yi‐Chang Chou, Shih‐Han Weng, Feng‐Shiang Cheng, Chih‐Hao Tseng, Hsiao‐Yun Hu, Chieh‐Hsing Liu   +5 more
wiley   +1 more source

Pharmacokinetics and Pharmacodynamics of Prusogliptin (DBPR108), a Once-Daily Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes. [PDF]

Clin Pharmacokinet
Liu W, Yang K, Lin Y, Lu C, Liu J, Zhou H, Wang J, Zhang T, Yao L, Qi H, Zhang X, Jia R, Li X, Jing S.   +13 more
europepmc   +1 more source

Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists for incident dementia: A retrospective multicohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1443-1452, February 2026.
Abstract Objective This study provides real‐world evidence on the comparative effectiveness of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) regarding the risk of incident dementia in adults with type 2 diabetes mellitus (T2DM).
Filippos Anagnostakis, Michail Kokkorakis, Shrihari Nagarajan, Georgia Anastasiou, Christos S. Mantzoros   +4 more
wiley   +1 more source

Evaluation of a Community Pharmacist-Led Intervention Program for Early Detection of Gastrointestinal Adverse Events of Dipeptidyl Peptidase-4 Inhibitors: A Multicenter, Non-Randomized Comparative Study. [PDF]

Pharmacy (Basel)
Funabashi A, Ito H, Maeda M, Hasegawa Y, Tsukioka R, Onda M.   +5 more
europepmc   +1 more source